Why is Balaxi Pharma falling/rising?

As of 16-Sep, Balaxi Pharmaceuticals Ltd is currently priced at 46.05, reflecting an increase of 0.76 or 1.68%. Today's performance indicates that the stock has outperformed its sector by 1.4%. However, it is important to note that while the stock is above its 5-day moving averages, it remains below its 20-day, 50-day, 100-day, and 200-day moving averages. The stock has shown a significant decline over the longer term, with a year-to-date return of -36.32% and a staggering -58.09% over the past year. Despite a strong long-term fundamental strength indicated by an average Return on Equity (ROE) of 30.97% and a fair valuation compared to peers, the stock's profits have decreased by -49.8%, contributing to its recent price movements.
In the broader market context, the stock's short-term performance of +0.09% over the past week is notably lower than the Sensex's gain of +1.49% during the same period. This underperformance is consistent with the stock's trend over the last three years, where it has consistently lagged behind the benchmark, generating -58.09% returns in the last year alone. Additionally, there has been a decline in institutional investor participation, with a -7.16% reduction in their stake, which may further impact market sentiment negatively. Overall, while there are some positive indicators, the combination of falling profits, reduced institutional interest, and consistent underperformance against benchmarks suggests a challenging environment for Balaxi Pharmaceuticals Ltd.